Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

View:
Post by DJDawg on Jun 20, 2024 11:12am

PP target

I remain intrigued by the PP having a goal of 10m as that is so much more than all the other times. I'd like to believe that they really do have some new buyers with deep pockets, giving them hopes of a bigger PP.

Even if the goal is 5m, that is still way more than they would have reason to get based on the last PP

Nov 2022 onwards, this is the proceeds of the previous PP
250k
1.2m
460k
1.2m
750k

So the last 5 PPs all add up to gross proceed of about 4m.

So they are truly delusional (which is worrisome to have with a mamagement team) or they have some interest that gives them expectation of being able to get the 5m+

Comment by CancerSlayer on Jun 20, 2024 12:00pm
My hands & feet are sweating ; ) In the meantime, considering our dependence on serial PPs, it seems the best strategy moving forward would be to "let the product drive the science, rather than the other way around", quoting the co-founder of Genentech, Robert Swanson....who happened to succumb to brain cancer/glioblastoma at age 52. What drives value the fastest when you have such ...more  
Comment by Legit62 on Jun 20, 2024 12:33pm
They have to have big buyers lined up or they would look like fools to pull in a mil, lets stay positive cause this PP could be the ticket to us climbing over the remaining hurdle,IMO. The SP is a cpmplete joke for what we have going on now
Comment by Dumbeldorfwhite on Jun 20, 2024 12:41pm
It's the people on this board that are delusional. Vera's the difference! Dr. Libarti is going to bring in big funds! BTD is days away! Its so easy to get the 450data after not having an adequate trial design! They ll say something interesting at AGM! it's groundhogs day here . Top dogs are having their pockets lined and money machine keeps going brrr while shareholders watch a ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250